



(51) International Patent Classification:

C07K 1/12 (2006.01) *C07K 7/50* (2006.01)
C12P 21/02 (2006.01) *C12N 9/52* (2006.01)

(21) International Application Number:

PCT/EP2013/069587

(22) International Filing Date:

20 September 2013 (20.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12185649.6 24 September 2012 (24.09.2012) EP

(71) Applicant: **DSM SINOCHEM PHARMACEUTICALS
NETHERLANDS B.V.** [NL/NL]; P.O.Box 245, Alexan-
der Fleminglaan 1, NL-2613 AX Delft (NL).

(72) Inventors: **LAAN, VAN DER, Jan Metske**; PO Box 4,
NL-6100 AA Echt (NL). **KERKMAN, Richard**; PO Box
4, NL-6100 AA Echt (NL). **LUITEN, Rudolf, Gijsbertus,
Marie**; P.O.Box 4, NL-6100 AA Echt (NL). **BERG, VAN
DEN, Marco Alexander**; P.O.Box 4, NL-6100 AA Echt
(NL).

(74) Agent: **VROOM, DE, Erik**; DSM Intellectual Property,
P.O. Box 4, NL-6100 AA Echt (NL).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHOD FOR PRODUCING A CYCLIC PEPTIDE

(57) Abstract: The present invention relates to a method for producing a cyclic peptide compound or a salt thereof which comprises contacting a cyclic lipopeptide compound or a salt thereof with an acylase derived from a microorganism belonging to the genus *Pseudomonas* to deacylate the lipid acyl moiety of said cyclic lipopeptide.



METHOD FOR PRODUCING A CYCLIC PEPTIDE

Field of the invention

5

The present invention relates to a method for producing a cyclic peptide compound or a salt thereof by deacylating the acyl chain of a cyclic lipopeptide by means of an acylase.

10

Background of the invention

Cyclic peptides or cyclopeptides are polypeptides in which the terminal amine and carboxyl groups form an internal peptide bond. Several cyclic peptides are known for their advantageous medicinal properties. In nature cyclic peptides can range from just a few amino acids in length to hundreds. Cyclic peptides can be naturally occurring compounds but may also be obtained by total synthesis or by synthetic or genetic modification of naturally occurring or naturally produced precursors. The latter class is referred to as semi synthetic cyclic peptides. When cyclic peptides bear one or more lipid tails or acyl chains, such cyclic peptides are referred to as cyclic lipopeptides. Cyclic lipopeptides with antibiotic activity include compounds such as daptomycin and amphomycin and an excellent example of cyclic lipopeptides is the class of echinocandins which are potent antifungals. Echinocandins are amphiphilic hexapeptides with an N-linked acyl lipid side chain and a molecular weight of approximately 1200 Da. Examples of medicinally useful echinocandins are the cyclic hexapeptides anidulafungin, caspofungin, cilofungin and micafungin which are useful in treating fungal infections, especially those caused by *Aspergillus*, *Blastomyces*, *Candida*, *Coccidioides* and *Histoplasma*. Anidulafungin (1-[(4*R*,5*R*)-4,5-dihydroxy-*N*2-[[4''-(pentyloxy)[1,1':4',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B), caspo-
fungin (1-[(4*R*,5*S*)-5-[(2-aminoethyl)amino]-*N*2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3*R*)-3-hydroxy-L-ornithine]-pneumocandin B₀) and micafungin (1-[(4*R*,5*R*)-4,5-dihydroxy-*N*2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4*S*)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]pneumocandin A₀) are

all semi synthetic cyclic hexapeptides derivable from naturally occurring echinocandins such as for instance echinocandin B, pneumocandin A₀, pneumocandin B₀ or FR 901379.

Natural cyclic lipopeptides are typically produced by micro-organisms. Daptomycin is produced by the soil bacterium *Streptomyces roseosporus*. Amphomycin is produced by *Streptomyces canus*. Natural echinocandins such as echinocandin B, echinocandin C, aculeacin A_y, pneumocandin B₀ and FR 901379 are also typically produced by various micro-organisms. For example, echinocandin B is produced by the fungus *Aspergillus nidulans* and FR 901379 is produced by the fungus *Coleophoma* *empetri*.

The acyl chain of cyclic lipopeptides has shown to be an important determinant of antifungal activity and toxicity (Debono M. & Gordee R.S., *Annu. Rev. Microbiol.* **48**, 471 (1994)). For instance the naturally occurring cyclic antifungal lipopeptide FR 901379 bearing a fatty acid acyl group attached to the N-terminus shows potent *in vivo* antifungal activity (Iwamoto, T., Fujie A., Nitta, K., Hashimoto, S., Okuhara, M., Kohsaka, M., *J. Antibiot.* **47**, 1092 (1994). Unfortunately, just like some other naturally occurring echinocandins it also shows high hemolytic activity. Enzymatic removal of the fatty acid chain and replacement for an octyloxybenzoyl acyl chain showed that the original activity of FR 901379 was retained but that hemolytic activity was significantly reduced. Another example is micafungin, which is produced by exchanging the lipid tail of FR 901379 for a complex 3,5-diphenyl substituted isoxazole acyl group (Fujie, *Pure Appl. Chem.* **79**, No. 4, pp.603-614 (2007)). Deacylation of the natural acyl chain of cyclic lipopeptides thus allows for the introduction of alternative side chains which improve antifungal efficacy and decrease hemolytic activity.

Deacylation of cyclic lipopeptides, such as echinocandins, has been established by means of the Aculeacin A acylase from *Actinoplanes utahensis*. JP 4228072(A) discloses an enzyme that catalyzes the deacylation of the lipid acyl portion of lipid cyclic peptide metabolites such as echinocandin B and aculeacin. JP 4075585 describes that this acylase can be cultured in *Streptomyces* as host organism. After Aculeacin A acylase is collected from a culture solution it is directly used to deacylate a substrate. In the course of optimizing the enzymatic deacylation it was discovered that some acylases of *Streptomyces* spp. were more efficient. EP 0885957 A1 describes cyclic lipopeptide acylases from the genus *Streptomyces* which are capable of deacylating

the acyl chain of a cyclic lipopeptide compound, e.g. the abovementioned echinocandin FR 901379 or analogs thereof and a method of producing a cyclic peptide compound which comprises using said acylases.

5 The disadvantage of the above described methods for deacylation of cyclic lipopeptides is that it is not possible to produce the abovementioned acylases in a functional form and in a sufficient amount in an industrially preferred production host such as *Escherichia coli* or *Bacillus*. Production of acylase in *Streptomyces* or *Actinoplanes utahensis* is not preferred in an industrial setting because it leads to relatively low enzyme yields because of low expression levels in these organisms and
10 because these organisms are less suitable for use in fermenter systems. For instance, use of *Streptomyces lividans* in fermenter systems often leads to problems with respect to viscosity which prevents that high cell densities are obtained. Furthermore, there is a problem with respect to downstream processing when abovementioned acylases are produced in *Streptomyces* or *Actinoplanes utahensis*. In these organisms the enzyme
15 seems to be attached to the biomass and in the purification process of the acylase enzyme extractions with high salt concentrations are required (EP0885957 A1, Kreuzman et al., 2000, Journal of Industrial Microbiology & Biotechnology, 24, 173-180, Ueda et al., 2011, Journal of Bioscience and Bioengineering 112, 409-414 Ueda et al., 2011, Journal of Antibiotics 64, 169-175). The use of salts to release an enzyme from
20 the broth is undesired at large scale industrial production with respect to corrosion and environmental issues.

In view of the strict regulatory and health related requirements there remains a need for improved purification and isolation methods. Therefore the present invention aims to improve deacylation of cyclic lipopeptides on industrial scale by providing a
25 method that applies an acylase that is producible in a functional form in an industrially preferred production host.

Detailed description of the invention

30 The present invention relates to a method for producing a cyclic peptide compound or a salt thereof which comprises contacting a cyclic lipopeptide compound or a salt thereof with an acylase derived from a microorganism belonging to the genus

Pseudomonas to deacylate the lipid acyl moiety of said cyclic lipopeptide. By using a *Pseudomonas* acylase in a method of producing cyclic peptides from cyclic lipopeptides it becomes possible to produce a cyclic peptide from a cyclic lipopeptide in a more efficient way because the *Pseudomonas* acylase can be produced in an efficient and large scale manner in an industrially preferred production organism. Accordingly the invention provides an important improvement in the production process of antibiotic cyclic peptides.

Following deacylation the obtained cyclic peptide may be subjected to an additional step of reacylating said cyclic peptide resulting in a reacylated cyclic peptide. This way a desired antibiotic product can be obtained. Reacylating the cyclic peptide usually involves a process of synthesizing the new acyl chain for the cyclic peptide, followed by a process of coupling the acyl chain to the free amino group of the cyclic peptide. After reacylation, the acyl chain of the reacylated cyclic peptide may be further processed resulting in a further processed reacylated cyclic peptide. This can be done by any suitable chemical, semi-chemical or enzymatic method. The process of reacylating is usually followed by purification of the thus obtained new cyclic lipopeptide to the right quality and/or crystal form.

A process of synthesizing a new acyl chain may be any method that is known to the skilled person such as total chemical synthesis or semi-synthesis, i.e. fermentation followed by one or more chemical conversions. One example of a process of reacylation of a cyclic peptide may be the chemical synthesis of an acyl chain from 1-bromooctane and 4-hydroxybenzoic acid followed by the coupling of the resulting 2,4,5-trichlorophenyl 4-(n-octyloxy)benzoate to a free amino group of a deacylated derivative of FR 901379 as described in Fujie, *Pure Appl. Chem.* 79, No. 4, pp.603-614 (2007).

The process of production of a cyclic lipopeptide according to the invention may for instance result in micafungin or a salt thereof. The reacylated cyclic peptide or further processed reacylated cyclic peptide described above may thus be micafungin or a salt thereof. The process of producing micafungin starts with production of FR 901379. This may be realized by fermentation by *Coleophoma empetri* followed by downstream processing to obtain the required purity of FR 901379 or a salt thereof.


In order to obtain micafungin, first the acyl side chain of FR 901379 has to be removed. For this purpose expression of the acylase from *Pseudomonas* in an industrially preferred production strain is realized, followed by downstream processing

and formulation of the enzyme. This is followed by the biocatalytic process in which the acyl side chain of FR 901379 is removed leading to a micafungin precursor.

In order to synthesize micafungin from its precursor first an appropriate side chain must be available. For micafungin this is a 3,5-diphenyl-substituted isoxazole. Side chains may be synthesized using techniques that are known to the skilled person. The side chain is subsequently coupled to the micafungin precursor by regular chemical, semi chemical or enzymatic methods. After optional further processing of the new acyl chain, micafungin is purified to obtain the right quality and crystal form. Any suitable method, which may be known to the skilled person for purification of the desired cyclic peptide to the right quality and/or crystal form may be applied.

Cyclic lipopeptide

The cyclic lipopeptide compound may be a cyclic lipopeptide such as daptomycin or amphomycin or a derivative thereof or a cyclic lipopeptide of the class of echinocandins. Preferably the cyclic lipopeptide is an echinocandin derivative. Echinocandins are compounds of general formula (1),



Formula (1)

wherein R is a hydrogen or an acyl group; R₁ is -H or -OH; R₂ is -H or -CH₃; R₃ is -H, -CH, -CH₂CONH₂ or -CH₂CH₂NH₂; R₄ is -H or -OH; R₅ is -OH, -OPO₃H₂, or -OSO₃H, R₆ is -H or -OSO₃H and R₇ is -H or CH₃.

Echinocandin derivatives may comprise any suitable enantiomer, and in a derivative R and R₁₋₇ may have a different designation than described above.

In case a salt of a cyclic lipopeptide is applied in the method of the invention, the preferred salts are conventional nontoxic mono- or di-salts. These include metal salts such as alkali metal salts, alkaline earth metal salts, ammonium salts, salts with organic bases, organic acid addition salts, inorganic acid addition salts and salts with amino acids.

An acyl (IUPAC name: alkanoyl) group is usually derived from a carboxylic acid.

The term "acyl" in "acylamino" or "acyl" group may include aliphatic acyl, aromatic acyl, heterocyclic acyl, aryl-substituted aliphatic acyl, and heterocyclic-substituted aliphatic acyl derived from carboxylic acids, carbonic acids, carbamic acids, and sulfonic acids.

The term acyl may include lower alkanoyl, higher alkanoyl, lower alkenoyl, higher alkenoyl, higher alkoxycarbonyl, ar(lower)alkoxycarbonyl, lower alkylsulfonyl, arylsulfonyl, ar(lower)alkylsulfonyl, aroyl, lower alkyl, higher alkyl, higher alkoxy, higher alkenyloxy, carboxy and aryloxy, including derivatives of these with any suitable substituent(s).

The acyl group to be deacylated while using the method of the invention is preferably a higher alkanoyl group, such as a fatty acid acyl group. Such an acyl group may for example be a palmitoyl group or a myristate group. Pneumocandins for example have a hydrophobic dimethylmyristate tail connected via an amide bond to the alpha-amino group of its hydroxylated ornithine residue.


An echinocandin derivative suitable for use in the method of the invention may be selected from the group consisting of FR 901379, echinocandin B, aculeacin A and pneumocandin A, B or C.

An echinocandin that may be particularly suited for the method of the invention is Substance FR 901379 or analogs thereof with the general formula (1), in which R is acyl, R₁ is -OH, R₂ is -CH₃, R₃ is CH₂C(O)NH₂, R₄ is -OH, R₅ is OH, R₆ is -OSO₃H and R₇ is CH₃.

Deacylation

In the present invention deacylation of a cyclic lipopeptide means that a side chain acylamino group of said cyclic lipopeptide is deacylated to an amino group.

For example, after deacylation of a cyclic lipopeptide of the class of echinocandins the deacylated compound is represented by the general formula (2),



Formula (2)

wherein R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are as defined above for Formula (1).

The deacylation reaction may take place in any suitable medium. The pH is preferably near physiological, for instance from 5 to 10, preferably from 6 to 9, still more preferably from 6.5 to 8.5 such as about 8, and may, if desired, be adjusted by adding an amount of acid or base. The temperature at which deacylation is carried out is not very critical and may be from 0 to 50°C, preferably from 5 to 40°C. A suitable temperature may for example be a temperature between 20 and 30°C.

Acylase

The acylase that is used to deacylate the lipid acyl moiety of a cyclic lipoprotein according to the method of the invention is an acylase produced by a microorganism belonging to the genus *Pseudomonas*, which includes *Pseudomonas* of the *Pseudomonas aeruginosa*, *Pseudomonas syringae*, *Pseudomonas putida*, *Pseudomonas pertucinogena*, *Pseudomonas fluorescens*, *Pseudomonas chlororaphis*

and *Pseudomonas stutzeri* groups. The acylase applied in the method of the invention is preferably derived from *Pseudomonas aeruginosa*.

The term "derived from" is meant to include an acylase that originates from a *Pseudomonas* species as well as an artificial variant thereof. Preferably the acylase originates from a *Pseudomonas* species. However, it is also possible that a gene encoding such said acylase is made artificially on the basis of a known gene or protein sequence such as the sequences SEQ ID NO: 1 and SEQ ID NO: 2 disclosed herein. It is also possible that a gene encoding said acylase originating from *Pseudomonas* is artificially modified, which may lead to an artificial variant of said acylase which may be applicable in the method of the invention.

Surprisingly the inventors have found that an acylase from *Pseudomonas* is capable of removing the acyl chain of cyclic lipopeptides. The major advantage of using an acylase of *Pseudomonas* is that these acylases can be conveniently expressed in industrially preferred production hosts. In the method of the invention the acylase is obtained from an organism transformed with a vector encoding an acylase derived from *Pseudomonas*. Such an organism may be a bacterium or a yeast and is preferably selected from the group consisting of *Escherichia coli*, *Bacillus*, *Pichia pastoris* and *Kluyveromyces lactis*. In principle a non-pathogenic *Pseudomonas* host may also be a good host organism to produce an acylase in. Such a non-pathogenic *Pseudomonas* host may be for instance *Pseudomonas alcaligenes*. The acylase may as well be produced in fungi, such as *Aspergillus nidulans*, *Aspergillus niger* and *Aspergillus oryzae*.

An acylase that is particularly preferred is the protein PvdQ of *Pseudomonas aeruginosa* PA01, which has the amino acid sequence as set forth in SEQ ID NO:1 (Huang et al., 2003 Appl. Environ. Microbiol. 69: 5941-5949), or a functional equivalent homologue thereof. PvdQ was initially identified as an acyl homoserine lactone (AHL) acylase (Sio et al, *Infect Immun.* 2006 Mar; 74 (3): 1673-82). AHL acylases can degrade AHLs to produce fatty acid and homoserine lactone. This way AHL acylases can regulate quorum sensing activity in the bacteria. Surprisingly however, such an AHL acylase can also be applied to deacylate cyclic lipopeptides.

In *Pseudomonas* the AHL acylases are initially produced as a protein consisting of a signal peptide, an N-terminal alpha subunit or small subunit, a C-terminal beta subunit or large subunit and a so-called spacer peptide between the small alpha and

the large beta subunit. Such a protein is referred to as preproprotein. The process of maturation of the preproprotein to an active enzyme comprises the removal of the signal peptide followed by an intramolecular cleavage of the remaining peptide chain into the small alpha and the large beta subunit and finally a part of the C-terminal amino acids of the small subunit (the spacer peptide) is removed. In the crude or purified enzyme preparation of the acylase used in the method, the acylase is preferably for a large part in its mature form.

The sequence set forth in SEQ ID NO: 1 represents a preproprotein and the gene with the sequence set forth in SEQ ID NO: 2 encodes this preproprotein. In case of SEQ ID NO: 1, the signal peptide is comprised in the amino acid residues 1-23. The size of the alpha subunit is approximately 18.5 kDa and the size of the beta subunit is approximately 60.4 kDa.

It will be understood that also functional derivatives of the acylase having the amino acid sequence of SEQ ID NO: 1 can be used in the method of the invention. The acylase used in the method of the invention therefore also encompasses derivatives and homologues of SEQ ID NO: 1. Protein sequences may be altered by substitutions, additions or deletions. Such protein sequences however may still encode functionally equivalent proteins or function-conservative variants. For example, several of the amino acids share similar properties. Arginine, lysine and histidine for example are positively charged at physiological pH. Aspartate and glutamate are negatively charged. Alanine, valine, isoleucine and leucine are small hydrophobic amino acids. Substitution of one or more amino acids within a protein sequence for another amino acid with the same properties therefore often leads to a functionally equivalent protein. For example, a substitution of valine for leucine within a protein sequence is usually not expected to influence protein functionality.

When the terms "homology", "sequence identity", "percent homology", or "percent identity" are used herein, they are used interchangeably. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the complete sequences are aligned for optimal comparison purposes. In order to optimize the alignment between the two sequences gaps may be introduced in any of the two sequences that are compared. Such alignment is carried out over the full length of the sequences being compared. Alternatively, the alignment may be carried out over a shorter length, for

example over about 20, about 50, about 100 or more nucleic acids/based or amino acids. The identity is the percentage of identical matches between the two sequences over the reported aligned region.

A comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. The skilled person will be aware of the fact that several different computer programs are available to align two sequences and determine the homology between two sequences (Kruskal, J. B. (1983) An overview of sequence comparison in D. Sankoff and J. B. Kruskal, (ed.), Time warps, string edits and macromolecules: the theory and practice of sequence comparison, pp. 1-44 Addison Wesley). The percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm for the alignment of two sequences. (Needleman, S. B. and Wunsch, C. D. (1970) *J. Mol. Biol.* 48, 443-453). The algorithm aligns amino acid sequences as well as nucleotide sequences. The Needleman-Wunsch algorithm has been implemented in the computer program NEEDLE. For the purpose of this invention the NEEDLE program from the EMBOSS package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice, P. Longden, I. and Bleasby, A. *Trends in Genetics* 16, (6) 276—277, <http://emboss.bioinformatics.nl/>). For protein sequences, EBLOSUM62 is used for the substitution matrix. For nucleotide sequences, EDNAFULL is used. Other matrices can be specified. The optional parameters used for alignment of amino acid sequences are a gap-open penalty of 10 and a gap extension penalty of 0.5. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.

Global Homology Definition

The homology or identity is the percentage of identical matches between the two full sequences over the total aligned region including any gaps or extensions. The homology or identity between the two aligned sequences is calculated as follows: Number of corresponding positions in the alignment showing an identical amino acid in both sequences divided by the total length of the alignment including the gaps. The identity defined as herein can be obtained from NEEDLE and is labeled in the output of the program as "IDENTITY".

Longest Identity Definition

The homology or identity between the two aligned sequences is calculated as follows: Number of corresponding positions in the alignment showing an identical amino acid in both sequences divided by the total length of the alignment after subtraction of the total number of gaps in the alignment. The identity defined as herein can be obtained from NEEDLE by using the NOBRIEF option and is labeled in the output of the program as "longest-identity". For purposes of the invention the level of identity (homology) between two sequences (amino acid or nucleotide) is calculated according to the definition of "longest-identity" as can be carried out by using the program NEEDLE.

The protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases, for example to identify other family members or related sequences. Such searches can be performed using the BLAST programs. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov>). BLASTP is used for amino acid sequences and BLASTN for nucleotide sequences. The BLAST program uses as defaults:

- Cost to open gap: default = 5 for nucleotides/ 11 for proteins
- Cost to extend gap: default = 2 for nucleotides/ 1 for proteins
- Penalty for nucleotide mismatch: default = -3
- Reward for nucleotide match: default = 1
- Expect value: default = 10
- Word size: default = 11 for nucleotides/ 28 for megablast/ 3 for proteins

Furthermore the degree of local identity (homology) between the amino acid sequence query or nucleic acid sequence query and the retrieved homologous sequences is determined by the BLAST program. However only those sequence segments are compared that give a match above a certain threshold. Accordingly the program calculates the identity only for these matching segments. Therefore the identity calculated in this way is referred to as local identity.

The acylase encoded by abovementioned vector that is used in the method of the invention therefore is a protein which has an amino acid sequence as set forth in

SEQ ID NO: 1, or an amino acid sequence with a sequence identity in the range between 50 and 100% thereto. Preferably said sequence identity is comprised between 60 and 100%, more preferably between 70 and 100%, more preferably between 80 and 100%, more preferably between 85 and 100%, more preferably between 90 and 100%,
5 more preferably between 95 and 100%, most preferably between 98 and 100%.

The acylase used in the method of the invention preferably encompasses acylases with a sequence identity of between 90 and 100% with the acylase protein of *Pseudomonas aeruginosa* PA01 represented by SEQ ID NO: 1 (or at least the mature acylase thereof). Such acylases are preferably derived from *Pseudomonas aeruginosa*
10 such as the acylases from *Pseudomonas aeruginosa* strains DK2, PAb1, M18, C3719, MPA01/P1, LESB58, PACS2, 39016, 2192, NCMG1179, PA7, PADK2_CF510.

Acylase preparation

The acylase preparation that is used in the method of the invention may be a
15 crude enzyme solution or a purified enzyme. The acylase preparation may also be composed of cells, either permeated or immobilized, that exhibit acylase activity or a homogenized cell suspension that exhibits acylase activity. Preferably, the acylase is produced in an industrially preferred production organism such as *Escherichia coli* in a fermenter. Cells are harvested and lysed with for instance a lysis buffer containing
20 lysozyme to prepare the acylase preparation. Preferably lysed cells are then centrifuged and the soluble protein fraction containing the acylase is used as a crude enzyme preparation in the method of the invention.

In a preferred embodiment of the invention the crude or purified enzyme solution of acylase has been obtained from a production host such as *Escherichia coli*. For this
25 purpose the gene encoding the acylase is isolated from the *Pseudomonas* genome, amplified and cloned into an expression vector. The expression vector can then be transformed into a host organism. Heterologous expression of a *Pseudomonas* acylase may be realized using various molecular biology techniques which are known to the skilled person.

30 Preferred alternative *Escherichia coli* host strains which can be used for industrial production of protein comprise *Escherichia coli* DH10B, *Escherichia coli* BL21, K12 strain RV308, *Escherichia coli* DH5, *Escherichia coli* JM109, *Escherichia coli* XL-1 and derivatives of these strains. Such derivatives may comprise specific knock-outs or

mutations which are beneficial for recombinant protein production and/or the use of certain desired markers and/or promoters. Various examples can be found at <http://wolfson.huji.ac.il/expression/bac-strains-prot-exp.html>.

If necessary a gene encoding said acylase can be synthesized in order to be
5 codon optimized for its host organism. Different organisms often show different preferences for one of the several codons that encode the same amino acid. Such a preference occurs when a greater frequency of a particular codon is found than expected by chance. Codon preference is thought to play a role in particular in fast-growing bacteria such as *Escherichia coli*, wherein the genomic tRNA pool reflects the
10 codon preference. If high amounts of proteins should be expressed in such an organism, optimal codons could help to achieve faster translation rates and thus more protein production. Codon optimization could in particular be relevant in case of heterologous expression as is the case in the present invention, wherein a *Pseudomonas* protein is expressed in a preferred industrial fermentation organism such
15 as *Escherichia coli*.

Another way to optimize protein production in a preferred industrial fermentation strain such as *Escherichia coli* may be to use an alternative signal peptide. As mentioned above, proteins such as the AHL acylase of *Pseudomonas* are initially synthesized as a preproprotein. The nucleotide sequence coding for the AHL acylase
20 without a signal peptide can be operably linked to a nucleotide sequence coding for a signal peptide from another species which also permits secretion of the preproprotein over the cytoplasmic membrane into the periplasm. Exchanging the signal peptide of a given protein for another might favor secretion of the protein in an industrially preferred production host organism and thus help to achieve more and faster protein production.

25 Further variations in expression constructs may be in promoters expressing the genes, way of induction or in copy number (low, medium, or high) of the plasmids.

Various expression constructs and expression hosts can be used. In preferred expression constructs the genes are expressed by either an inducible or a constitutive promoter using a low, medium, or high copy expression vector.

EXAMPLES

Example 1

Deacylation of a cyclic lipopeptide

5 A detailed description of how the method of the invention may be performed is disclosed in the following example. Although this example describes the deacylation of pneumocandin B₀ and FR 901379 the skilled person will acknowledge that the methods presented in this example will be well applicable for other cyclic lipopeptides.

Gene cloning and expression hosts

Expression using an *Escherichia coli* expression matrix

SEQ ID NO: 2 represents the DNA sequence of the gene encoding the wild-type acylase from *Pseudomonas aeruginosa* PA01 with its native signal peptide. The amino
15 acid sequence of the protein encoded by this DNA sequence is set forth in SEQ ID NO: 1. The signal peptide represents residues 1-23 of SEQ ID NO: 1. This gene was re-cloned from the original vector used by the synthesis vendor (DNA2.0) into a pTAC low copy expression vector behind a wild-type IPTG inducible tac promoter using specific restriction sites. Subsequently the expression construct was transformed
20 into an *Escherichia coli* DH10B expression host. Recombinant colonies were selected by antibiotic resistance (kanamycin) and analyzed by restriction digestion. Bacteria were grown *in duplo* in 24 wells microtiter plates using conditions as follows.

24 wells microtiter plate fermentations

25 Individual colonies were grown overnight in 3 ml 2xTY medium (in presence and absence of 100 µg/ml kanamycin) in 24 wells microtiter plates at 30°C and 550 rpm. Subsequently the fermentation broth was diluted 1:100 in 24 wells microtiter plates at 30°C and 550 rpm using Slow Glucose Release Medium (in presence or absence of 100 µg/ml kanamycin). Cultures were grown for another 48 hours after adding 50 µM
30 IPTG. After freezing and thawing the cell pellets were resuspended in lysis buffer and centrifuged. The supernatant (soluble fraction) was used for qualitative SDS-PAGE analysis using NuPAGE MOPS buffer and SeeBlue plus2 marker. Proteins were visualized by staining with Instant Blue.

Qualitative SDS-PAGE

The expression of the acylase gene was analyzed using qualitative SDS-PAGE. For qualitative SDS-PAGE the cell pellets were collected by centrifugation at 14,000 rpm for 1 minute in a bench-top Eppendorf centrifuge and were dissolved in lysis buffer (100 mM Tris/HCl, 0.1 mg/ml DNase, 2.0 mg/ml Lysozyme, 25 μ M MgSO₄) and incubated for 30 minutes at 37°C. Samples were fractionated by centrifugation and lysed cell pellets were centrifuged for 1 minute at 14,000 rpm in a bench-top Eppendorf centrifuge and the soluble protein fraction was transferred into a fresh mini tube. Pellets were dissolved in an equal volume of the Phosphate Buffered Saline (PBS) buffer. 6.5 μ l of the supernatant and 6.5 μ l of the pellet fraction were used for SDS-PAGE analysis.

Shake flask fermentations

Bacteria were grown using conditions as described in the previous paragraph. Final growth is performed in a 100 ml shake-flask, with foam plug, containing 10 mL medium, at 30°C and 280 rpm.

Sample pre-treatment for activity assay

For the activity assay the bacteria were grown in Slow Glucose Release Medium (in presence or absence of 100 μ g/ml kanamycin) in 100 mL Shake-Flask. Selected strains were grown using conditions as described above. Cell pellets were collected by centrifugation at 14,000 rpm for 1 minute in a bench-top Eppendorf centrifuge and were dissolved in lysis buffer (100 mM Tris/HCl, 0.1 mg/ml DNase, 2.0 mg/ml Lysozyme, 25 μ M MgSO₄) and incubated for 30 minutes at 37°C. Samples were fractionated by centrifugation and lysed cell pellets were centrifuged for 1 minute at 14,000 rpm in a bench-top Eppendorf centrifuge and the soluble protein fraction was transferred into a fresh mini tube.

Deacylation of pneumocandin B₀

After shake-flask fermentation of *Escherichia coli* expressing the *Pseudomonas aeruginosa* acylase gene the ability of the produced acylase to deacylate pneumocandin B₀ was determined. The enzyme reactions were performed according to the following conditions:

4 ml 100 mM di-potassium hydrogen phosphate pH 8.0;

Add 0.5 ml 1 mg/ml pneumocandin B₀ (dissolved in MeOH);

Add 0.5 ml sample (soluble protein fraction containing the acylase).

Reaction temperature: 40°C

5 Reaction time: 1 hour

The enzyme reaction was stopped by dilution of the reaction mixture with 2% phosphoric acid 1:1 (v/v). Subsequently the reaction mixture was applied to a UPLC chromatography system coupled to a mass spectrometer for the determination of pneumocandin B₀ (substrate), deacylated pneumocandin B₀ (product) and its hydrolysis product (deacylated pneumocandin B₀-H₂O).

Deacylation of FR 901379

After shake-flask fermentation of *Escherichia coli* expressing the *Pseudomonas aeruginosa* acylase gene the ability of the acylase to deacylate FR 901379 was determined. The enzyme reactions were performed according to the following conditions:

4 ml 100 mM di-potassium hydrogen phosphate pH 8.0;

Add 0.5 ml 1 mg/ml FR 901379 (dissolved in MeOH);

Add 0.5 ml sample (soluble protein fraction containing the acylase)

20 Reaction temperature: 40°C

Reaction time: 1 hour

The enzyme reaction was stopped by dilution of the reaction mixture with 2% phosphoric acid 1:1 (v/v). Subsequently the reaction mixture was applied to a UPLC chromatography system coupled to a mass spectrometer for the determination of FR 901379 (substrate), deacylated FR 901379 (product) and its hydrolysis product (deacylated FR 901379-H₂O).

Method of analysis

Reaction products were analyzed using UPLC connected to a mass spectrometer for detection.

Column: Waters UPLC HSS T3 1.8um 2.1 * 100 mm I.D 1.7 um

Mobile phase A 50 mM Ammonium acetate

Mobile phase B 75% acetonitrile

Column temp. 40°C

Flow 0.35 ml/min

Gradient for pneumocandin B₀:

Time (min)	0	3	5	6	5.2	8
%A	98	90	10	10	98	98
%B	2	10	90	90	2	2

5 Gradient for FR 901379:

Time (min)	0	3	5	6	5.2	8
%A	98	75	10	10	98	98
%B	2	25	90	90	2	2

Mass spectrometer Instrument Parameters - Function 1:

	Polarity	ES+
	Calibration	Static 1
10	Capillary (kV)	3.00
	Cone (V)	40.00
	Extractor (V)	1.00
	RF Lens (V)	1.0
	Source Temperature (°C)	120
15	Desolvation Temperature (°C)	350
	Cone Gas Flow (L/h)	100
	Desolvation Gas Flow (L/h)	500 496
	LM 1 Resolution	15.0
	HM 1 Resolution	15.0
20	Ion Energy 1	0.5
	Entrance	40
	Collision	0
	Exit	40
	LM 2 Resolution	15.0
25	HM 2 Resolution	15.0
	Ion Energy 2	0.5
	Multiplier (V)	700

Syringe Pump Flow (uL/min) 20.0
 Gas Cell Pirani Pressure (mbar) <1e-4 mbar

Since neither standards of deacylated pneumocandin B₀ and deacylated FR 901379, nor standards of the corresponding hydrolysis products or labeled internal standards of pneumocandin B₀ and FR 901379 were available, only qualitative analysis of these components was performed. Therefore the results are only estimation and they are not corrected for any matrix effect (ion suppression in mass spectrometry, etc.).

Results

Expression of the *Pseudomonas aeruginosa* acylase

SDS PAGE analysis showed that the acylase from *Pseudomonas aeruginosa* was expressed in the *Escherichia coli* DH10B strain. The correct sizes of the alpha subunit (18.5 kDa) and beta subunit (60.4 kDa) were detected in the soluble fraction.

Table 1: Peak areas of deacylated pneumocandin B₀, its hydrolysis product and pneumocandin B₀

Sample name	deacylated pneumocandin B ₀	hydrolysis product	pneumocandin B ₀
Blank			123881
<i>Escherichia coli</i> empty strain			139014
<i>Escherichia coli</i> + pTAC_SEQ ID NO: 2	1376	2653	121497

After shake-flask fermentation, lysis and recovery of the soluble fraction as described, the activity of the supernatant containing the acylase of the invention was tested on pneumocandin B₀. Table 1 shows the activity of different samples after shake-flask fermentation on pneumocandin B₀. In this table the peak area of deacylated pneumocandin B₀, its hydrolysis product and pneumocandin B₀ are presented. As blank sample (Blank), a reaction without enzyme (or sample) is performed. In addition, to correct for any possible background from the expression host an empty strain (DH10B) was also included. In both the blank sample and in the sample to which the cell free extract of the empty production strain was added only the pneumocandin B₀ peak was observed. When incubated with the cell free extract of the cells expressing the acylase

(DH10B + pTAC_SEQ ID NO: 2) both deacylated pneumocandin B₀ and its hydrolysis product are observed. The presence of these components shows that the acylase which was characterized as an acyl homoserine lactone acylase does also show deacylating activity for the cyclic lipopeptide pneumocandin B₀ resulting in the desired deacylated pneumocandin B₀ and the free acyl side chain.

In separate experiment the shake-flask fermentation, lysis and recovery of the soluble fraction were repeated and the activity of the supernatant containing the acylase of the invention was tested on FR 901379. Table 2 shows the activity of different samples after shake-flask fermentation on FR 901379.

Table 2: Peak areas of deacylated FR 901379, its hydrolysis product and FR 901379

Sample name	deacylated FR 901379	hydrolysis product	FR 901379
Blank			109857
<i>Escherichia coli</i> empty strain			194490
<i>Escherichia coli</i> + pTAC_SEQ ID NO: 2	4808	605	51673

After incubation of FR 901379 with the cell free extract of an *Escherichia coli* fermentation producing the *Pseudomonas aeruginosa* acylase both deacylated FR 901379 and its hydrolysis product are observed. The presence of these components shows that the acylase which was shown to deacylate pneumocandin B₀ is also able to deacylate the cyclic lipopeptide FR 901379 resulting in the desired deacylated FR 901379 and the free acyl side chain.

Conclusions

The acylase from *Pseudomonas aeruginosa* shows activity towards cyclic lipopeptides. A vector encoding the amino acid sequence as set forth in SEQ ID NO: 1 is therefore suitable for use in the method of the invention. This example shows that by using a *Pseudomonas* acylase in a method of producing cyclic peptides from cyclic lipopeptides it becomes possible to produce a cyclic peptide from a cyclic lipopeptide in an efficient way. The method of the invention makes it possible to produce a cyclic peptide from a cyclic lipopeptide in an efficient way, because the *Pseudomonas* acylase can be

produced in an industrially preferred production organism (in this example *Escherichia coli*).

In case of pneumocandin B₀ the acylase cleaves off a 10,12-dimethyl-myristoyl acyl moiety. Another cyclic lipopeptide containing a 10,12-dimethyl-myristoyl acyl moiety is sporiofungin A. Given the deacylation of pneumocandin B₀ it is very likely the acylase will also deacylate sporiofungin A. In case of FR 901379 the acylase cleaves off a palmitoyl acyl moiety. Aculeacin A, FR 209602 and cryptocandin also carry the palmitoyl acyl moiety and therefore are also suitable to be deacylated by the acylase.

Example 2

Conserved residues of the acylase of the invention

In the following example the active site residues of the acylase used in the method of the invention were determined by computational studies.

For this purpose the 3D structure of the mature quorum quenching n-acyl homoserine lactone acylase from *Pseudomonas aeruginosa* PA01 (PvdQ, represented by amino acid residues 24 to 762 of SEQ ID NO: 1) as determined by M. Bokhove *et al.* (2010), *Proc Natl Acad Sci USA* 107, 686-691 was taken as a model. The atomic coordinates are available from the Protein Data Bank by accession code 2WYB. The inventors used the molecular modeling package Maestro (Schrödinger) to visualize the 3D structure of 2WYB which contains a covalently bound dodecanoic acid in the active site. The dodecanoic acid was used to map the active site of the acylase in order to determine the amino acids that contribute to its substrate specificity which surprisingly includes the deacylation of cyclic lipopeptides.

Residues in the active site can be divided in so-called first shell amino acids and second shell amino acids. The first shell amino acids are those amino acids which interact directly with the dodecanoic acid via electrostatic interactions, hydrogen bonding, hydrophobic interactions and/or van der Waals forces. Apart from the first shell amino acids which interact directly with the dodecanoic acid also the second shell amino acids are considered. The second shell residues are identified by measuring which amino acids have at least one atom within a sphere of 7 Angstroms around a first shell amino acid.

The inventors used the dodecanoic acid as a guide to determine the docking of cyclic lipopeptides (e.g. pneumocandin B₀, FR 901379) into the active site. The resulting

complexes can be used to extend the mapping of the active site towards the cyclic peptide moiety of the substrate in the same way as described for the dodecanoic acid. In order to generate a 3D model for homologous amino acid sequences originating from a *Pseudomonas* species or synthetic variants thereof for which no experimental 3D structure is available comparative modeling using the modeling software package Prime (Schrödinger) was applied. It should be understood that alternative software tools with similar functionality are available for comparative modeling e.g. Yasara, Modeler, Swiss-Model, etc., and will lead to the same results. By superimposing the active site which was mapped previously according to the procedure as described above onto the 3D model of the homologous protein originating from a *Pseudomonas* species or an artificial variant thereof, it can be established whether the given homologous protein can be expected to also exhibit deacylation activity for cyclic lipopeptides. Homologous proteins in this aspect originate from *Pseudomonas* species and show at least 50% sequence identity (such as 60, 70, 80, 85, 90, 95, or 98 % sequence identity) with SEQ ID NO: 1. The person skilled in the art will understand that such homologous proteins may be derived from original *Pseudomonas* wild type genes or from artificial variants thereof.

Comparative modeling of the active site performed as described above revealed that an acylase usable in the method of the invention typically contains the following sequence motifs:

- i) D-X₄-[V or T]-X₂-L-[L or M]-X₃-G;
- ii) [L or I]-P-G-L-P-X₂-N;
- iii) R-V-L-X₂-W; and
- iv) H-T-V-D-X₃-H,

wherein X_n is a sequence of unspecified amino acid residues of length "n". For instance, X₄ means X-X-X-X, which indicates that four sequential positions may contain any amino acid residue. Amino acid residues within brackets, like [V or T], indicates that the amino acid residue at this position may be V or T.

Motif i) corresponds, as determined by protein sequence alignment, to the amino acid residues at positions 161-174 of SEQ ID NO: 1, wherein the amino acid residues V or T at position 166, L at position 169 and L or M at position 170 are first shell residues contacting the substrate.

Motif ii) corresponds, as determined by protein sequence alignment, to the amino acid residues at positions 266-273 of SEQ ID NO: 1, wherein the amino acid residues L or I at position 266, L at position 269 and N at position 273 are first shell residues contacting the substrate.

5 Motif iii) corresponds, as determined by protein sequence alignment, to the amino acid residues at positions 373-378 of SEQ ID NO: 1, wherein the amino acid residues V at position 374, L at position 375 and W at position 378 are first shell residues contacting the substrate.

10 Motif iv) corresponds, as determined by protein sequence alignment, to the amino acid residues at positions 284-291 of SEQ ID NO: 1, wherein the amino acid residues H at position 284, T at position 285 and V at position 286 are first shell residues contacting the substrate.

For these reasons, the vector used in the method of the invention preferably encodes an acylase that has an amino acid sequence that has between 50 and 100 % (such as
15 between 50, 60, 70, 80, 85, 90, 95 or 99 and 100%) sequence identity with respect to the amino acid sequence set forth in SEQ ID NO: 1, wherein the amino acid sequence of said acylase contains the following sequence motifs:

- i) D-X₄-[V or T]-X₂-L-[L or M]-X₃-G (SEQ ID NO: 3);
- ii) [L or I]-P-G-L-P-X₂-N (SEQ ID NO: 4);
- 20 iii) R-V-L-X₂-W (SEQ ID NO: 5); and
- iv) H-T-V-D-X₃-H (SEQ ID NO: 6),

wherein X_n is a sequence of unspecified amino acid residues of length "n".

SEQUENCE LISTING

<110> DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.

5 <120> Method for producing a cyclic peptide

<130> 29068-WO-PCT

<150> EP12185649.6

10 <151> 2012-09-24

<160> 6

<170> BiSSAP 1.2

15

<210> 1

<211> 762

<212> PRT

<213> *Pseudomonas aeruginosa*

20

<220>

<223> wild-type acylase from *P. aeruginosa* PA01

<400> 1

25 Met Gly Met Arg Thr Val Leu Thr Gly Leu Ala Gly Met Leu Leu Gly
 1 5 10 15
 Ser Met Met Pro Val Gln Ala Asp Met Pro Arg Pro Thr Gly Leu Ala
 20 25 30
 Ala Asp Ile Arg Trp Thr Ala Tyr Gly Val Pro His Ile Arg Ala Lys
 30 35 40 45
 Asp Glu Arg Gly Leu Gly Tyr Gly Ile Gly Tyr Ala Tyr Ala Arg Asp
 50 55 60
 Asn Ala Cys Leu Leu Ala Glu Glu Ile Val Thr Ala Arg Gly Glu Arg
 65 70 75 80
 35 Ala Arg Tyr Phe Gly Ser Glu Gly Lys Ser Ser Ala Glu Leu Asp Asn
 85 90 95
 Leu Pro Ser Asp Ile Phe Tyr Ala Trp Leu Asn Gln Pro Glu Ala Leu
 100 105 110
 Gln Ala Phe Trp Gln Ala Gln Thr Pro Ala Val Arg Gln Leu Leu Glu
 115 120 125
 40 Gly Tyr Ala Ala Gly Phe Asn Arg Phe Leu Arg Glu Ala Asp Gly Lys
 130 135 140
 Thr Thr Ser Cys Leu Gly Gln Pro Trp Leu Arg Ala Ile Ala Thr Asp
 145 150 155 160
 45 Asp Leu Leu Arg Leu Thr Arg Arg Leu Leu Val Glu Gly Gly Val Gly
 165 170 175
 Gln Phe Ala Asp Ala Leu Val Ala Ala Ala Pro Pro Gly Ala Glu Lys
 180 185 190
 Val Ala Leu Ser Gly Glu Gln Ala Phe Gln Val Ala Glu Gln Arg Arg
 195 200 205
 50 Gln Arg Phe Arg Leu Glu Arg Gly Ser Asn Ala Ile Ala Val Gly Ser
 210 215 220
 Glu Arg Ser Ala Asp Gly Lys Gly Met Leu Leu Ala Asn Pro His Phe
 225 230 235 240
 55 Pro Trp Asn Gly Ala Met Arg Phe Tyr Gln Met His Leu Thr Ile Pro
 245 250 255
 Gly Arg Leu Asp Val Met Gly Ala Ser Leu Pro Gly Leu Pro Val Val
 260 265 270
 Asn Ile Gly Phe Ser Arg His Leu Ala Trp Thr His Thr Val Asp Thr

			275				280				285						
	Ser	Ser	His	Phe	Thr	Leu	Tyr	Arg	Leu	Ala	Leu	Asp	Pro	Lys	Asp	Pro	
		290					295					300					
5	Arg	Arg	Tyr	Leu	Val	Asp	Gly	Arg	Ser	Leu	Pro	Leu	Glu	Glu	Lys	Ser	
	305					310					315					320	
	Val	Ala	Ile	Glu	Val	Arg	Gly	Ala	Asp	Gly	Lys	Leu	Ser	Arg	Val	Glu	
					325					330					335		
	His	Lys	Val	Tyr	Gln	Ser	Ile	Tyr	Gly	Pro	Leu	Val	Val	Trp	Pro	Gly	
				340					345					350			
10	Lys	Leu	Asp	Trp	Asn	Arg	Ser	Glu	Ala	Tyr	Ala	Leu	Arg	Asp	Ala	Asn	
			355					360					365				
	Leu	Glu	Asn	Thr	Arg	Val	Leu	Gln	Gln	Trp	Tyr	Ser	Ile	Asn	Gln	Ala	
		370				375						380					
15	Ser	Asp	Val	Ala	Asp	Leu	Arg	Arg	Arg	Val	Glu	Ala	Leu	Gln	Gly	Ile	
	385					390					395					400	
	Pro	Trp	Val	Asn	Thr	Leu	Ala	Ala	Asp	Glu	Gln	Gly	Asn	Ala	Leu	Tyr	
				405						410					415		
	Met	Asn	Gln	Ser	Val	Val	Pro	Tyr	Leu	Lys	Pro	Glu	Leu	Ile	Pro	Ala	
				420					425					430			
20	Cys	Ala	Ile	Pro	Gln	Leu	Val	Ala	Glu	Gly	Leu	Pro	Ala	Leu	Gln	Gly	
			435					440					445				
	Gln	Asp	Ser	Arg	Cys	Ala	Trp	Ser	Arg	Asp	Pro	Ala	Ala	Ala	Gln	Ala	
		450				455					460						
25	Gly	Ile	Thr	Pro	Ala	Ala	Gln	Leu	Pro	Val	Leu	Leu	Arg	Arg	Asp	Phe	
	465					470					475					480	
	Val	Gln	Asn	Ser	Asn	Asp	Ser	Ala	Trp	Leu	Thr	Asn	Pro	Ala	Ser	Pro	
				485						490					495		
	Leu	Gln	Gly	Phe	Ser	Pro	Leu	Val	Ser	Gln	Glu	Lys	Pro	Ile	Gly	Pro	
				500					505					510			
30	Arg	Ala	Arg	Tyr	Ala	Leu	Ser	Arg	Leu	Gln	Gly	Lys	Gln	Pro	Leu	Glu	
			515					520					525				
	Ala	Lys	Thr	Leu	Glu	Glu	Met	Val	Thr	Ala	Asn	His	Val	Phe	Ser	Ala	
		530					535					540					
35	Asp	Gln	Val	Leu	Pro	Asp	Leu	Leu	Arg	Leu	Cys	Arg	Asp	Asn	Gln	Gly	
	545					550					555					560	
	Glu	Lys	Ser	Leu	Ala	Arg	Ala	Cys	Ala	Ala	Leu	Ala	Gln	Trp	Asp	Arg	
				565						570					575		
	Gly	Ala	Asn	Leu	Asp	Ser	Gly	Ser	Gly	Phe	Val	Tyr	Phe	Gln	Arg	Phe	
				580					585					590			
40	Met	Gln	Arg	Phe	Ala	Glu	Leu	Asp	Gly	Ala	Trp	Lys	Glu	Pro	Phe	Asp	
			595					600					605				
	Ala	Gln	Arg	Pro	Leu	Asp	Thr	Pro	Gln	Gly	Ile	Ala	Leu	Asp	Arg	Pro	
		610					615					620					
45	Gln	Val	Ala	Thr	Gln	Val	Arg	Gln	Ala	Leu	Ala	Asp	Ala	Ala	Ala	Glu	
	625					630					635					640	
	Val	Glu	Lys	Ser	Gly	Ile	Pro	Asp	Gly	Ala	Arg	Trp	Gly	Asp	Leu	Gln	
				645						650					655		
	Val	Ser	Thr	Arg	Gly	Gln	Glu	Arg	Ile	Ala	Ile	Pro	Gly	Gly	Asp	Gly	
				660					665					670			
50	His	Phe	Gly	Val	Tyr	Asn	Ala	Ile	Gln	Ser	Val	Arg	Lys	Gly	Asp	His	
			675					680					685				
	Leu	Glu	Val	Val	Gly	Gly	Thr	Ser	Tyr	Ile	Gln	Leu	Val	Thr	Phe	Pro	
		690					695					700					
55	Glu	Glu	Gly	Pro	Lys	Ala	Arg	Gly	Leu	Leu	Ala	Phe	Ser	Gln	Ser	Ser	
	705					710					715					720	
	Asp	Pro	Arg	Ser	Pro	His	Tyr	Arg	Asp	Gln	Thr	Glu	Leu	Phe	Ser	Arg	
				725						730					735		
	Gln	Gln	Trp	Gln	Thr	Leu	Pro	Phe	Ser	Asp	Arg	Gln	Ile	Asp	Ala	Asp	
				740					745					750			
60	Pro	Gln	Leu	Gln	Arg	Leu	Ser	Ile	Arg	Glu							

755 760

<210> 2
 <211> 2289
 5 <212> DNA
 <213> *Pseudomonas aeruginosa*

<220>
 <221> source
 10 <222> 1..2289
 <223> /organism="Pseudomonas aeruginosa"
 /note="gene encoding the acylase from *Pseudomonas aeruginosa* PA01"
 /mol_type="unassigned DNA"

15 <400> 2
 atggggatgc gtaccgtact gaccggcctg gccggcatgc tgttgggttc gatgatgccg 60
 gtccaggccg atatgccgcg gccgaccggg ctggccgcgg atatccgctg gaccgcctat 120
 20 ggcgtgccgc acatccgggc caaggatgag cgcggcctgg gctatggcat cggctacgcc 180
 tacgcgcgcg acaacgcctg cctgctggcc gaggagatcg tcaccgcgcg cggcgagcgg 240
 gcgcgctatt tcggcagcga gggcaagtcg tcggccgagc tggacaacct gccgtccgac 300
 25 atcttctacg cctggctcaa ccaacccgag gcgctgcaag ccttctggca ggcgcagacg 360
 cccgcggtac gccagttgct cgaaggctac gccgccggtt tcaaccgctt cctccgcgag 420
 30 gccgacggca agaccaccag ttgccttggc cagccctggc tgcggggccat cgcgaccgat 480
 gacctgctgc gcctgacccg gcgcctgctg gtcgaaggcg gggtcggcca gttcgccgac 540
 gcgctggtgg ccgccgcgcc gcccgagcgc gagaaggtcg ccttgagcgg cgagcaggcg 600
 35 ttccaggctc ccgagcagcg gcgccagcgc ttccgcctgg agcgcggcag caacgccatt 660
 gccgttgga gcgaacgttc ggcgacggc aagggcatgc tcctggccaa cccgcacttc 720
 40 ccctggaacg gcgcgatgcg tttctaccag atgcacctga ccattcccgg ccggctcgac 780
 gtgatggggg cctcgctgcc cggcctgccg gtggtcaaca tcggcttcag ccgccacctg 840
 gcctggaccc acacggtgga tacctccagc cacttcaccc tgtatgcct ggcgctggac 900
 45 ccgaaggacc cgcggcgcta cctggttgac ggtcgttcgc tgccgctgga ggagaagtcc 960
 gtcgcgatcg aggtgcgcgg cgccgacggc aagctgtcgc gcgtcgagca caaggtctac 1020
 50 cagtcgatct acggcccgtg ggtggtctgg cccggcaagc tggactggaa ccgcagcgag 1080
 gcctatgcgc tgcgtgacgc caacctggag aacactcggg tactgcaaca gtggtactcg 1140
 atcaaccagg ccagcgacgt cgccgacctg cgccggcgcg tcgaggcgct acagggtatc 1200
 55 ccctgggtca acaccctggc cgcgacgag cagggcaacg ccctgtacat gaaccagtcg 1260
 gtggtgccct acctgaagcc ggaactgatc cccgcctgcg ccattccgca actggtcgcc 1320
 60 gaaggcctgc cgccctcca ggggcaggac agccgctgtg cctggagtcg cgaccgggcc 1380

gcggcccagg ctggcatcac cccggcggcg caactgccgg tgctgttgcg cagggacttc 1440
 gtgcagaact ccaacgacag cgcttggtg accaaccgg cgagcccgct gcaaggcttc 1500
 5 tcgcccctgg tcagccagga gaagcccatc ggtccgcggg cgcgctacgc cctgagccgg 1560
 ctacagggca agcagccgct ggaggcgaag acgctggagg agatggtcac cgccaaccat 1620
 10 gtcttcagcg ccgaccaggt gctgccggac ctgctccgcc tgtgccgcga caaccagggc 1680
 gagaagtccc ttgcccgcgc ctgcgcggcc ctggcgcagt gggaccgtgg cgccaacctc 1740
 gacagcggca gcggcttcgt ctacttccag cgcttcatgc aacgcttcgc cgaactcgac 1800
 15 ggcgcgtgga aggaaccgtt cgatgcgcaa cgtcccctgg atacgccgca aggcatcgcc 1860
 ctcgaccggc cgcaggtggc gaccaggtg cgccaggcgc tggcggacgc ggccggcgag 1920
 20 gtggagaaga gcgggattcc cgacggcgcg cgctggggcg acctgcaagt gagcaccgct 1980
 ggccaggaac gcatcgcgat tcccggcggc gatggccatt tcggggtcta caacgcgac 2040
 cagagcgtcc gcaagggcga ccacctggag gtggtcggcg gcactagcta catccagctg 2100
 25 gtgaccttcc ccgaggaagg tcctaaggct cgcggggtgc tggctttctc ccagtccagc 2160
 gatccgcgct cgccgcacta ccgcgaccag accgagctgt tttcccgcca gcaatggcag 2220
 30 accttgccgt tcagcgacag gcagatcgac gccgaccgc aactgcaacg gctaagcatt 2280
 cgcgaatga 2289
 <210> 3
 35 <211> 14
 <212> PRT
 <213> Pseudomonas
 <220>
 40 <223> motif i)
 <220>
 <221> VARIANT
 <222> join(2..5,7..8,11..13)
 45 <223> may be replaced with any amino acid
 <220>
 <221> VARIANT
 <222> 6
 50 <223> may be replaced with Val
 <220>
 <221> VARIANT
 <222> 10
 55 <223> may be replaced with Met
 <400> 3
 Asp Leu Leu Arg Leu Thr Arg Arg Leu Leu Val Glu Gly Gly
 1 5 10
 60

<210> 4
<211> 8
<212> PRT
<213> Pseudomonas
5
<220>
<223> motif ii)

<220>
10 <221> VARIANT
<222> 1
<223> may be replaced with Ile

<220>
15 <221> VARIANT
<222> 6..7
<223> may be replaced with any amino acid

<400> 4
20 Leu Pro Gly Leu Pro Val Val Asn
1 5

<210> 5
<211> 6
25 <212> PRT
<213> Pseudomonas

<220>
<223> motif iii)
30
<220>
<221> VARIANT
<222> 4..5
<223> may be replaced with any amino acid
35
<400> 5
Arg Val Leu Gln Gln Trp
1 5

40 <210> 6
<211> 8
<212> PRT
<213> Pseudomonas

45 <220>
<223> motif iv)

<220>
50 <221> VARIANT
<222> 5..7
<223> may be replaced with any amino acid

<400> 6
55 His Thr Val Asp Thr Ser Ser His
1 5

CLAIMS

1. A method for producing a cyclic peptide compound or a salt thereof which comprises contacting a cyclic lipopeptide compound or a salt thereof with an acylase derived from a microorganism belonging to the genus *Pseudomonas* to deacylate said cyclic lipopeptide.
2. The method according to claim 1, comprising an additional step of reacylating said cyclic peptide resulting in a reacylated cyclic peptide.
3. The method according to claim 2, wherein the acyl chain of said reacylated cyclic peptide is further processed resulting in a further processed reacylated cyclic peptide.
4. The method according to any of the claims 1-3, wherein said acylase is obtained from an organism transformed with a vector encoding an acylase derived from *Pseudomonas*.
5. The method according to claim 4, wherein said organism is selected from the group consisting of *Escherichia coli*, *Bacillus*, *Pseudomonas alcaligenes*, *Pichia pastoris* and *Kluyveromyces lactis*.
6. The method according to claim 4 or 5, wherein the acylase encoded by said vector is a protein which has an amino acid sequence as set forth in SEQ ID NO: 1 or an amino acid sequence with a sequence identity in the range between 50 to 100% thereto.
7. The method according to claim 6, wherein the amino acid sequence of said protein contains the following sequence motifs:
 - i) D-X₄-[V or T]-X₂-L-[L or M]-X₃-G (SEQ ID NO: 3);
 - ii) [L or I]-P-G-L-P-X₂-N (SEQ ID NO: 4);
 - iii) R-V-L-X₂-W (SEQ ID NO: 5); and
 - iv) H-T-V-D-X₃-H (SEQ ID NO: 6),wherein X_n is a sequence of unspecified amino acid residues of length "n".

8. The method according to any of the claims 4-7, wherein the vector encodes the amino acid sequence as set forth in SEQ ID NO: 1.
- 5 9. The method according to any of the claims 1-8, wherein said acylase is derived from *Pseudomonas aeruginosa*.
10. The method according to any of the claims 1-9, wherein said cyclic lipopeptide is an echinocandin derivative.
- 10 11. The method according to claim 10, wherein the echinocandin derivative is selected from the group consisting of aculeacin A, cryptocandin, echinocandin B, FR 209602, FR 901379, pneumocandins A, B and C and sporiofungin.
- 15 12. The method according to any of the claims 2-11, wherein said reacylated cyclic peptide or said further processed reacylated cyclic peptide is micafungin or a salt thereof.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/069587

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K1/12 C12P21/02 C07K7/50 C12N9/52
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K C12P C12Y C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BEILSTEIN Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHOJI J ET AL: "The amino acid sequence of cerexin A (studies on antibiotics from the genus Bacillus. VII.", THE JOURNAL OF ANTIBIOTICS OCT 1975, vol. 28, no. 10, October 1975 (1975-10), pages 764-769, XP55089971, ISSN: 0021-8820 page 765, paragraph 5. -----	1-12
X	YUKIO KIMURA ET AL: "Polymyxin Acylase: a New Enzyme for Preparing Starting Materials for Semisynthetic Polymyxin Antibiotics", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 51, no. 6, 1 January 1987 (1987-01-01), pages 1617-1623, XP055089976, DOI: 10.1271/bbb1961.51.1617 abstract ----- -/-	1,2,4,5, 9-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 January 2014

Date of mailing of the international search report

17/01/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Vogt, Titus

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/069587

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIMURA E A: "Polymixin acylase: purification and characterization, with special reference to broad substrate specificity", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM, TOKYO, JP, vol. 53, no. 2, 1 January 1989 (1989-01-01), pages 497-504, XP002149548, ISSN: 0002-1369 abstract -----	1,2,4,5, 9-11
X	WO 01/05815 A1 (LILLY CO ELI [US]; KREUZMAN ADAM JOSEPH [US]; KULANTHAIVEL PALANIAPPAN) 25 January 2001 (2001-01-25) claims -----	1,4,5, 9-11
X	WO 2006/063783 A1 (SANOFI AVENTIS DEUTSCHLAND [DE]; EHLERS EBERHARD [DE]; DECKER HEINRICH) 22 June 2006 (2006-06-22) page 13, line 3 - page 14, line 2; claims page 9, line 4 - line 13 -----	1-5,9-11
A	S.-Y. PARK ET AL: "Identification of Extracellular N-Acylhomoserine Lactone Acylase from a Streptomyces sp. and Its Application to Quorum Quenching", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 71, no. 5, 1 May 2005 (2005-05-01), pages 2632-2641, XP055089940, ISSN: 0099-2240, DOI: 10.1128/AEM.71.5.2632-2641.2005 figure 2 -----	1-12
A	CHEN CHIN-NUNG ET AL: "A probable aculeacin A acylase from the Ralstonia solanacearum GMI1000 is N-acyl-homoserine lactone acylase with quorum-quenching activity", BMC MICROBIOLOGY, BIOMED CENTRAL LTD, GB, vol. 9, no. 1, 9 May 2009 (2009-05-09), page 89, XP021048261, ISSN: 1471-2180, DOI: 10.1186/1471-2180-9-89 Abstract; AAC is 38% identical to PvdQ. ----- -/--	1-12

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/069587

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. BOKHOVE ET AL: "The quorum-quenching N-acyl homoserine lactone acylase PvdQ is an Ntn-hydrolase with an unusual substrate-binding pocket", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 2, 12 January 2010 (2010-01-12), pages 686-691, XP055090606, ISSN: 0027-8424, DOI: 10.1073/pnas.0911839107 the whole document -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/069587

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0105815	A1	25-01-2001	
		AU 5310600 A	05-02-2001
		BR 0012481 A	02-04-2002
		CA 2378868 A1	25-01-2001
		CN 1361791 A	31-07-2002
		EP 1198471 A1	24-04-2002
		HU 0202315 A2	28-10-2002
		JP 2003505042 A	12-02-2003
		MX PA02000458 A	02-07-2002
		NO 20020183 A	13-03-2002
		WO 0105815 A1	25-01-2001

WO 2006063783	A1	22-06-2006	
		AT 394416 T	15-05-2008
		DE 102004060750 A1	13-07-2006
		DK 1828228 T3	01-09-2008
		EP 1828228 A1	05-09-2007
		ES 2304736 T3	16-10-2008
		HR P20080290 T3	31-07-2008
		JP 4922182 B2	25-04-2012
		JP 2008523789 A	10-07-2008
		PT 1828228 E	04-07-2008
		SI 1828228 T1	31-08-2008
		US 2008076149 A1	27-03-2008
		WO 2006063783 A1	22-06-2006
